FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018231624> ?p ?o ?g. }

• W2018231624 endingPage "2850" @default.
• W2018231624 startingPage "2842" @default.
• W2018231624 abstract "Reverse transcriptase (RT) inhibitors are emerging as a novel class of anticancer differentiating agents, active in several human tumor cell models, such as melanoma and prostate, thyroid and colon carcinoma. Indeed, much evidence suggests that they may act by inhibiting endogenous RT, a gene highly expressed in undifferentiated and transformed cells. We therefore evaluated whether endogenous RT may represent a new molecular target in the treatment of human renal clear-cell carcinoma, a neoplasm with very low sensitivity to standard pharmacological therapies. Efavirenz and nevirapine, 2 non-nucleosidic RT inhibitors commonly used in HIV patients, either induced a reversible downregulation of cell proliferation or enhanced cell differentiation in primary cultures of human renal carcinoma cells characterized by high levels of endogenous RT activity. Both agents upregulated the expression of the vitamin D receptor and calbindin 28k genes, which are constitutively expressed in renal tubular cells, and induced vitamin D signaling by enhancing the ability of tumor cells to upregulate the vitamin D-dependent gene, CYP24. Furthermore, efavirenz- and nevirapine-differentiated tumor cells exhibited an immunogenic phenotype with an increased expression of HLA-I and CD40 antigens and an enhanced ability to elicit a specific T-cell response in mixed lymphocyte/tumor-cell cultures. Indeed, renal carcinoma cells exposed to efavirenz induced a CD8+CCR7-CD45RA− effector memory T-cell phenotype, whereas untreated RCC cells induced a CD8+CCR7+CD45RA− central memory T-cell phenotype. These data suggest that RT inhibitors may be a novel tool in the treatment of human renal clear-cell carcinoma, potentially able to enhance the immunogenic potential of tumor cell. © 2008 Wiley-Liss, Inc." @default.
• W2018231624 created "2016-06-24" @default.
• W2018231624 creator A5001391327 @default.
• W2018231624 creator A5002442524 @default.
• W2018231624 creator A5012446712 @default.
• W2018231624 creator A5025291956 @default.
• W2018231624 creator A5025640800 @default.
• W2018231624 creator A5043335285 @default.
• W2018231624 creator A5044817949 @default.
• W2018231624 creator A5046454960 @default.
• W2018231624 creator A5047049372 @default.
• W2018231624 creator A5050569543 @default.
• W2018231624 creator A5056638224 @default.
• W2018231624 date "2008-01-01" @default.
• W2018231624 modified "2023-10-07" @default.
• W2018231624 title "Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma" @default.
• W2018231624 cites W1216325924 @default.
• W2018231624 cites W1667816862 @default.
• W2018231624 cites W184990260 @default.
• W2018231624 cites W1964181260 @default.
• W2018231624 cites W1967980459 @default.
• W2018231624 cites W1990765972 @default.
• W2018231624 cites W2003192353 @default.
• W2018231624 cites W2007451610 @default.
• W2018231624 cites W2008423758 @default.
• W2018231624 cites W2009478438 @default.
• W2018231624 cites W2010841793 @default.
• W2018231624 cites W2011113891 @default.
• W2018231624 cites W2017095842 @default.
• W2018231624 cites W2021681883 @default.
• W2018231624 cites W2024564405 @default.
• W2018231624 cites W2025593087 @default.
• W2018231624 cites W2026734902 @default.
• W2018231624 cites W2029128444 @default.
• W2018231624 cites W2030090912 @default.
• W2018231624 cites W2035353932 @default.
• W2018231624 cites W2036012806 @default.
• W2018231624 cites W2041881143 @default.
• W2018231624 cites W2047389487 @default.
• W2018231624 cites W2057835336 @default.
• W2018231624 cites W2057940509 @default.
• W2018231624 cites W2060136712 @default.
• W2018231624 cites W2080109637 @default.
• W2018231624 cites W2090832589 @default.
• W2018231624 cites W2112552541 @default.
• W2018231624 cites W2113847305 @default.
• W2018231624 cites W2114161855 @default.
• W2018231624 cites W2114781384 @default.
• W2018231624 cites W2117854357 @default.
• W2018231624 cites W2119390857 @default.
• W2018231624 cites W2127099198 @default.
• W2018231624 cites W2132607362 @default.
• W2018231624 cites W2142334951 @default.
• W2018231624 cites W2148284955 @default.
• W2018231624 cites W2150800455 @default.
• W2018231624 cites W2151249459 @default.
• W2018231624 cites W2151590954 @default.
• W2018231624 cites W2153253704 @default.
• W2018231624 cites W2156079175 @default.
• W2018231624 cites W2162697298 @default.
• W2018231624 cites W2164356694 @default.
• W2018231624 doi "https://doi.org/10.1002/ijc.23197" @default.
• W2018231624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18351578" @default.
• W2018231624 hasPublicationYear "2008" @default.
• W2018231624 type Work @default.
• W2018231624 sameAs 2018231624 @default.
• W2018231624 citedByCount "37" @default.
• W2018231624 countsByYear W20182316242012 @default.
• W2018231624 countsByYear W20182316242013 @default.
• W2018231624 countsByYear W20182316242014 @default.
• W2018231624 countsByYear W20182316242015 @default.
• W2018231624 countsByYear W20182316242016 @default.
• W2018231624 countsByYear W20182316242017 @default.
• W2018231624 countsByYear W20182316242019 @default.
• W2018231624 countsByYear W20182316242020 @default.
• W2018231624 countsByYear W20182316242021 @default.
• W2018231624 countsByYear W20182316242022 @default.
• W2018231624 crossrefType "journal-article" @default.
• W2018231624 hasAuthorship W2018231624A5001391327 @default.
• W2018231624 hasAuthorship W2018231624A5002442524 @default.
• W2018231624 hasAuthorship W2018231624A5012446712 @default.
• W2018231624 hasAuthorship W2018231624A5025291956 @default.
• W2018231624 hasAuthorship W2018231624A5025640800 @default.
• W2018231624 hasAuthorship W2018231624A5043335285 @default.
• W2018231624 hasAuthorship W2018231624A5044817949 @default.
• W2018231624 hasAuthorship W2018231624A5046454960 @default.
• W2018231624 hasAuthorship W2018231624A5047049372 @default.
• W2018231624 hasAuthorship W2018231624A5050569543 @default.
• W2018231624 hasAuthorship W2018231624A5056638224 @default.
• W2018231624 hasBestOaLocation W20182316241 @default.
• W2018231624 hasConcept C104317684 @default.
• W2018231624 hasConcept C125593758 @default.
• W2018231624 hasConcept C154317977 @default.
• W2018231624 hasConcept C202751555 @default.
• W2018231624 hasConcept C203014093 @default.
• W2018231624 hasConcept C502942594 @default.
• W2018231624 hasConcept C55493867 @default.
• W2018231624 hasConcept C86803240 @default.

• next